Lumos Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 09, 2023 at 04:36 pm EDT
Share
Lumos Pharma, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 0.527 million compared to USD 0.403 million a year ago. Net loss was USD 8.93 million compared to USD 7.84 million a year ago. Basic loss per share from continuing operations was USD 1.09 compared to USD 0.94 a year ago.
For the six months, revenue was USD 1.22 million compared to USD 0.514 million a year ago. Net loss was USD 16.28 million compared to USD 15.56 million a year ago. Basic loss per share from continuing operations was USD 1.98 compared to USD 1.86 a year ago.
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing its clinical program and focused on identifying, acquiring, developing, and commercializing products and new therapies for people with rare diseases. Its pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (GH) secretagogue, also called ibutamoren, for rare endocrine disorders that require injectable recombinant human growth hormone (rhGH). LUM-201 is a tablet formulation that is intended to be administered once daily. LUM-201 stimulates GH via the GH secretagogue receptor (GHSR1a), also known as the ghrelin receptor, and also suppresses the release of somatostatin, thus providing a differentiated mechanism of action to treat some rare endocrine disorders (involving a deficiency of GH) by increasing the amplitude of endogenous, pulsatile GH secretion. Lumos Pharma Sub, Inc. (Private Lumos) is its subsidiary.
LUMOS PHARMA, INC. 
